AG真人官方

Color Star Technology Co., Ltd. (NASDAQ: ADD) reported the results of its 29 June 2025 Annual General Meeting in a Form 6-K filing. Holders of 17,083,723 ordinary shares, representing 57.9 % of outstanding shares, formed a quorum and approved every agenda item.

Key resolutions:

• Reverse Share Split & Share Consolidation: Board may implement a reverse split at a ratio between 1-for-5 and 1-for-100. This reduces the share count and raises the par value while keeping authorised capital at US$32 million. Vote: 99.0 % in favour (16.92 m For / 0.16 m Against).
• Corporate Rebrand: Company name will change to Zeta Network Group. Vote: 99.3 % in favour (16.97 m For).
• Articles Amendment: Adoption of a Seventh Amended & Restated Memorandum and Articles to reflect the share consolidation and name change (99.3 % support).
• 2025 Equity Incentive Plan: Authorises new share-based awards; passed with 99.1 % support.
• Board Elections: Five directors (Wei Zhang, Hung-Jen Kuo, Honglei Jiang, Yan Zhang, Samantha Huang) re-elected with ~99.2 % approval each.
• Auditor Ratification: Assentsure PAC retained for FY 2025 (99.5 % approval).
• Routine filings and adjournment authorities also approved.

Implications for investors: The reverse split authority provides flexibility to lift a depressed share price or meet exchange listing requirements, but may compress existing shareholdings depending on the final ratio chosen. The equity plan could introduce dilution over time, while the rebrand signals a strategic repositioning. No financial performance metrics were disclosed in this filing.

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has launched a follow-on public offering consisting of 2,482,692 shares of common stock and pre-funded warrants for up to 1,363,469 additional shares. The securities are priced at $19.50 per share (warrant price $19.4999; exercise price $0.0001).

The base deal will generate $75.0 million in gross proceeds. After underwriting fees of 6 % ($1.17 per share) and estimated expenses, net proceeds are expected to be $69.8 million. Underwriters hold a 30-day option for 576,923 extra shares that would lift gross proceeds to $86.3 million and net proceeds to roughly $80.4 million. The financing increases shares outstanding to 36.5 million (37.1 million if the option is exercised) before any warrant conversion.

Use of proceeds: funds will support clinical development of lead EGFR inhibitor firmonertinib, advance other oncology pipeline programs, and provide general working capital.

Clinical backdrop: Firmonertinib holds FDA Breakthrough Therapy and Orphan Drug designations. Interim data show 79 % ORR in EGFR exon-20 NSCLC (FAVOUR) and 68 % ORR at a 240 mg dose in PACC mutations (FURTHER), with favourable CNS activity and no Grade 4/5 TRAEs. A global Phase 3 PACC study (ALPACCA 鈥� FURMO-006) is scheduled to begin 2H 2025.

Capital structure impacts: investors will see an immediate book-value dilution of $12.32 per share. Additional dilution is possible from 4.1 million outstanding stock options (WAEP $14.96), 3.8 million shares reserved for future awards, 3.4 million shares already sold under an at-the-market facility, and any exercise of the new pre-funded warrants. ArriVent also owes up to $765 million in milestones to its partner Shanghai Allist for global rights to firmonertinib.

Key terms of the pre-funded warrants: no expiration, exercisable any time for $0.0001 per share, subject to 4.99 %/9.99 % beneficial-ownership caps, and will not be listed for trading.

Timeline: closing and delivery are expected on or about 3 July 2025.

Expro Group Holdings N.V. (XPRO) filed a Form 4 disclosing equity grants to its newly reported Chief Financial Officer, Sergio L. Maiworm Jr. On 30 June 2025, the executive received two separate awards of restricted stock units (RSUs):

• 286,041 RSUs that cliff-vest on 30 June 2028.
• 42,792 RSUs that vest one-third each on 30 June 2026, 2027 and 2028.

The combined 328,833 RSUs represent the CFO鈥檚 entire reported beneficial ownership following the transactions. Both awards were granted as inducement awards under NYSE Rule 303A.08 and were acquired at $0 cost, implying no open-market purchase or sale of common stock. No derivative securities were involved, and no dispositions were reported.

The multi-year vesting schedules aim to encourage long-term value creation, while the issuance of new shares introduces a modest dilutive element. No other financial metrics, sales, or option exercises were disclosed in the filing.

Everi Holdings Inc. (EVRI) has filed Post-Effective Amendment No. 1 to twelve prior Form S-8 registration statements that collectively covered more than 48 million shares issued under a variety of legacy equity incentive plans. The amendment formally deregisters all unsold shares that remained available under those plans.

The filing follows the July 1, 2025 closing of a multi-party transaction under which funds managed by affiliates of Apollo Global Management (through Voyager Parent, LLC) simultaneously acquired both Everi and International Game Technology PLC鈥檚 (IGT) Gaming & Digital business. Key transaction steps included:

• IGT鈥檚 transfer of substantially all Gaming & Digital assets and liabilities to a new subsidiary, Ignite Rotate LLC (鈥淪pinco鈥�).
• Buyer鈥檚 purchase of all Spinco units from IGT and, through an affiliate, all shares of IGT Canada Solutions ULC.
• Merger: Voyager Merger Sub, Inc. merged with and into Everi, leaving Everi as a wholly-owned subsidiary of Buyer.

Because Everi鈥檚 common stock is being delisted and deregistered under Section 12(b) of the Exchange Act, the company is terminating all related Securities Act offerings. The amendment therefore renders the referenced S-8 registration statements ineffective and removes any remaining unsold shares from registration. Signatures from the full board and senior officers, including President & CEO Randy L. Taylor and CFO Mark F. Labay, authorize the filing.

Investor takeaway: the amendment is an administrative step confirming that Everi鈥檚 equity will no longer trade publicly or be issued under employee stock plans following completion of the Apollo-led acquisition.

The Free Writing Prospectus outlines the key terms of Morgan Stanley Finance LLC鈥檚 Contingent Income Auto-Callable Securities linked to the S&P U.S. Equity Momentum 40% VT 4% Decrement Index (ticker: SPUMP40). The notes offer a contingent coupon of 9.00%-10.00% per annum, paid monthly if the index closes at or above the 50% coupon-barrier on the relevant observation date. Beginning one year after issuance, the securities are auto-callable quarterly at par if the index is at or above its initial level (100% call threshold). If not redeemed early, investors receive par at maturity on 1 Aug 2030 provided the index has not fallen more than 50%. Should the index close below the 50% downside threshold on the final observation date, principal is reduced 1-for-1, exposing investors to substantial loss (e.g., a 51% decline delivers $490 per $1,000 note).

The issue price is $1,000, but Morgan Stanley鈥檚 estimated value is $882.50 (卤$32.50), reflecting embedded fees and hedging costs. The notes are unsecured, unsubordinated obligations of Morgan Stanley Finance LLC, fully guaranteed by Morgan Stanley, and will not be listed on any exchange, limiting secondary-market liquidity. Key risks include credit exposure to Morgan Stanley, potential loss of principal, lack of upside participation beyond coupon payments, early-redemption reinvestment risk, tax uncertainty, and the limited operating history and leveraged methodology of the underlier, which incorporates a 4% annual decrement.

• Issuer: Morgan Stanley Finance LLC (guaranteed by Morgan Stanley)
• Maturity: 5 years (Aug 1 2030) with quarterly call from year 1
• Barriers: 50% coupon & downside threshold; 100% call threshold
• CUSIP: 61778NEA5 | Pricing date: 28 Jul 2025 | Estimated value: $882.50

Form 144 highlights for Shimmick Corporation (SHIM)

The filing discloses a proposed sale of 916 common shares (aggregate market value $1,567.28) through TD Securities on or about June 27, 2025. The seller, Mitchell B. Goldsteen, is an affiliate of the company; the form does not state his exact role but lists his Irvine, CA business address. Total outstanding shares are 34,361,459, so the proposed sale equals roughly 0.003 % of outstanding stock.

The filing also details Goldsteen鈥檚 trading activity over the prior three months. Between March 27 and June 26, 2025, he sold 鈮�170,733 shares for total gross proceeds of roughly $300,000 (sum of line-item proceeds), equal to about 0.50 % of shares outstanding. Individual daily sales ranged from 500鈥�13,386 shares, executed almost every trading day, indicating a systematic divestment pattern.

No new financial, operational or strategic information about Shimmick is provided; Form 144 is strictly a notice of intent to sell. Goldsteen certifies that he is not in possession of undisclosed material adverse information and, if relying on Rule 10b5-1, that the plan was adopted in good faith. The filing is categorized as LIVE.

Investor takeaway: The notice itself covers a very small additional sale, but it confirms ongoing insider selling activity. While the absolute percentage is minor, investors often monitor insider trends for sentiment signals. No direct impact on EPS, liquidity, or corporate strategy can be inferred from this document alone.

Shimmick Corporation (SHIM) Form 4 filing: Director and 10% owner Mitchell B. Goldsteen disclosed two small open-market sales executed under a pre-arranged Rule 10b5-1 plan adopted 20 Aug 2024.

• 26 Jun 2025: sold 7,122 common shares at a weighted-average price of $1.69.
• 27 Jun 2025: sold 916 common shares at a weighted-average price of $1.71.

Total shares sold: 8,038. Following the transactions, Goldsteen鈥攖hrough his wholly owned GOHO, LLC鈥攃ontinues to hold 21,384,776 shares of Shimmick common stock. Ownership remains indirect (I); the filer disclaims beneficial ownership beyond his pecuniary interest.

The sales represent less than 0.04 % of Goldsteen鈥檚 post-transaction stake and therefore appear immaterial to the overall ownership structure. No derivative transactions were reported.

The Form 144 filed on 26 June 2025 notifies the SEC of a planned insider sale by Mitchell B. Goldsteen, an affiliate of Shimmick Corporation (NASDAQ: SHIM). The notice covers the prospective disposition of 7,122 common shares through TD Securities (USA) LLC at an aggregate market value of $12,040.45. Given the company鈥檚 34,361,459 shares outstanding, the planned sale equals roughly 0.02 % of the float, indicating limited dilution or ownership impact.

The shares were originally acquired on 09 December 2020 in a private transaction with GOHO LLC, when Goldsteen obtained 21.91 million shares. The insider certified that he possesses no non-public adverse information and is acting under a Rule 10b5-1 trading plan adopted on 20 August 2024.

The filing also discloses a history of frequent open-market sales between 26 March and 25 June 2025. These transactions involve dozens of small blocks that collectively amount to tens of thousands of shares and generate cumulative proceeds of approximately $280 k (based on line-item totals). None of the individual sales exceed Rule 144 thresholds, but the pattern reflects ongoing liquidity activity by the insider.

From an investment perspective, the notice signals continued but modest insider selling rather than a material change in ownership structure. Investors may wish to track additional Form 144 or Form 4 filings to determine whether the cadence or size of sales accelerates, which could carry stronger valuation implications.

Mitchell B. Goldsteen, a Director and 10% Owner of Shimmick Corp (SHIM), reported multiple sales transactions of common stock executed through a pre-established Rule 10b5-1 trading plan from June 23-25, 2025. The transactions included:

• June 23: Sale of 6,000 shares at weighted average price of $1.60
• June 24: Sale of 4,250 shares at weighted average price of $1.66
• June 25: Sale of 900 shares at weighted average price of $1.59

Following these transactions, Goldsteen indirectly owns 21,392,814 shares through GOHO LLC, where he serves as sole managing member. The sales were executed according to a Rule 10b5-1 plan established on August 20, 2024. Goldsteen disclaims beneficial ownership of these securities except for his pecuniary interest. The transactions demonstrate systematic selling activity by a significant insider while maintaining substantial holdings.